InterFuse Intensive Treatment Lines

Let's get the most important thing about this product out of the way upfront. SkinBetter Science's InterFuse Intensive Treatment Lines is often marketed — not by SkinBetter themselves, but by the broader peptide-skincare conversation — as a kind of 'topical Botox.' It is not that. Nothing topical is that. The muscle-signaling peptides in this formula (Argireline and Syn-Ake) do have some published clinical evidence for modest reduction in expression line depth when applied consistently over weeks, but the magnitude of effect is nowhere near what an injected neurotoxin produces. If dramatic line reduction is what you're after, the answer is a needle, not a tube. What this treatment can honestly offer is a targeted, topical supplement — a tool for people who don't want injectables, who are between injection appointments and want some topical support, or who specifically want to address the shallower expression lines where injectables would be overkill. Set expectations there, and the product has a defensible case.

What's actually in the tube is a more thoughtful combination than the simple 'Argireline cream' label suggests. You get acetyl hexapeptide-8 (Argireline), which mimics the N-terminal end of the SNAP-25 protein involved in neurotransmitter release and mildly inhibits the muscle contraction signaling at the neuromuscular junction. You get dipeptide diaminobutyroyl benzylamide diacetate (Syn-Ake), a synthetic peptide inspired by temple viper venom that blocks the same pathway through a different receptor — the postsynaptic nicotinic acetylcholine receptor. The pairing of two muscle-signaling peptides operating on different points of the same pathway is the theoretical case for compound efficacy beyond what either alone can deliver. Layered on top of that, you have the same three-peptide matrikine stack used in the regular InterFuse eye cream (palmitoyl tripeptide-38, palmitoyl tetrapeptide-7, and acetyl tetrapeptide-5), which signals to fibroblasts to upregulate collagen and hyaluronic acid synthesis. So the formula is working on expression lines from two distinct biological angles: mild relaxation of the muscle contractions that form the lines, plus stimulation of the collagen and hyaluronic acid that fills and supports the skin from underneath. Add supporting ingredients — niacinamide for barrier strength, sodium hyaluronate for immediate surface smoothing, squalane and ceramide NP for the vehicle — and you have a formulation that's trying to do several things well rather than depending on any single miracle active.

The immediate experience is where the short-term appeal of this treatment lives. On first application, the hyaluronic acid gives you a visible smoothing effect that looks like early results — but it's mostly surface plumping from water binding, which wears off within hours. The matte finish of the cream also visually blurs the appearance of fine lines the way a good silicone primer does. Those immediate effects are not the long-term story, but they're genuine, and they're what makes users feel like the product is 'working' during the first few days while the actual peptide effects are too early to show. After eight to twelve weeks of consistent twice-daily application directly to the targeted expression lines — crow's feet, forehead lines, the '11s' between the brows — you can expect modest softening of line depth. Subtle. Not dramatic. Real, but measurable more by a dermatologist with a grid photo than by your morning mirror.

The applicator is worth commenting on. Unlike the jar format of the regular InterFuse eye cream, this product comes in a small squeeze tube with a narrow applicator tip, which is the right choice for a targeted spot treatment. You dispense a tiny amount — really tiny, smaller than you'd expect — and pat it directly onto the specific line or line cluster you're targeting. Full-face application is a mistake with this product; it wastes the expensive peptide concentration and empties the 9g tube in a month. Used correctly as a targeted spot treatment, the tube lasts four to five months, which helps the value math somewhat. The tube design also protects the peptides better than a jar would, since there's no air exposure with each use.

Where the formulation has real questions is in the independent clinical evidence for the muscle-signaling peptide category. Argireline has been studied for nearly twenty years, and the evidence supports modest effects on expression line depth — but most of the published studies are small, industry-funded, or methodologically limited. Syn-Ake has even less independent evidence. The strongest case you can make for these peptides is that they have some measurable effect at the right concentrations with consistent long-term use, and that the effect is safe, reversible, and well-tolerated. The weakest case — and the honest one — is that the magnitude of effect is on the order of what a good hyaluronic acid serum can produce through surface hydration alone, and it's genuinely hard to distinguish the peptide effect from the baseline smoothing effect of the rest of the formula without controlled comparison.

Who should actually buy this: patients who've made an informed decision not to pursue injectables but still want to do something topical for expression lines, patients using this as a supplementary step between injection appointments to maintain topical support, and patients already committed to the SkinBetter regimen whose dermatologist has recommended this as part of a structured plan. Who should skip: anyone hoping this will replace or significantly delay the need for injectables, anyone who wants dramatic visible results, anyone looking for a full-face anti-aging treatment (this is targeted, not broad-spectrum), and anyone on a budget. At $160 for 9 grams, this is among the most expensive products in the SkinBetter lineup on a per-gram basis, and the value argument depends entirely on whether the subtle topical effect is meaningful to you personally.

Final take: a genuinely thoughtful topical treatment for expression lines that delivers modest, cumulative results with consistent use — but one whose marketing history has often oversold what muscle-signaling peptides can accomplish. If you set expectations realistically and use it as a targeted spot treatment rather than a full-face cream, it has a defensible place in a dermatology-guided routine. If you go in expecting injectable-equivalent results, you'll be disappointed by a product that was never actually designed to compete with a needle.

Formula

The Science

The active premise of this treatment rests on two biological mechanisms: muscle-signaling peptide activity at the neuromuscular junction, and matrikine-driven fibroblast stimulation. Acetyl hexapeptide-8 (Argireline) was developed in the early 2000s and has been studied in multiple small clinical trials; a 2002 paper in the International Journal of Cosmetic Science (Blanes-Mira et al.) demonstrated that Argireline mimics the N-terminal portion of SNAP-25 and competitively inhibits vesicle docking at the presynaptic neuromuscular junction, reducing neurotransmitter release. A 2013 clinical study in Clinical, Cosmetic and Investigational Dermatology reported that topical Argireline at 10% reduced periorbital wrinkle depth by approximately 17% over 30 days — measurable but modest compared to the typical 40-60% reduction seen with injected neurotoxins. The evidence for Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is more limited, with most published data coming from the manufacturer. Matrikine peptides, by contrast, have stronger theoretical backing based on Maquart et al.'s foundational work on fragment-based fibroblast signaling, and palmitoyl tripeptide-38 in particular has been studied for its effects on collagen I, III, and hyaluronic acid synthesis. The honest summary of the evidence: muscle-signaling peptides produce measurable but modest effects on expression line depth at the right concentrations with consistent use; matrikine peptides support collagen and hyaluronic acid synthesis with similar modest, gradual effects. Combined, they represent a reasonable topical strategy for patients who want to supplement or avoid injectables — but not a substitute for the dramatic effects that neurotoxin injections produce.

References

1. A synthetic hexapeptide (Argireline) with antiwrinkle activity — International Journal of Cosmetic Science (2002)

Dermatologist Perspective

Dermatologists generally view muscle-signaling peptide creams as supplementary tools rather than replacements for injectable neurotoxins. Board-certified dermatologists note that topical peptides can produce measurable but modest effects on expression line depth with consistent long-term use and are appropriate for patients who prefer to avoid injectables or who want to maintain topical support between injection appointments. This treatment is commonly offered in dermatology offices as a targeted option for patients with mild expression lines or as an adjunct for patients already receiving in-office procedures. Dermatologists also emphasize that managing patient expectations is critical with this product category — the topical effect is real but subtle, and comparing it directly to injectable neurotoxin results sets patients up for disappointment.

Guidance

Launched in 2018 as an extension of the InterFuse line, this treatment was positioned for patients who wanted a targeted topical option for expression lines — particularly between sessions of neurotoxin injections, or for patients who preferred to avoid injectables entirely. Dermatologists use it as an adjunct rather than a replacement for in-office procedures.

About SkinBetter Science Emerging Brand (2–5 years)

SkinBetter Science launched in 2016 as a physician-dispensed brand. The InterFuse Treatment Lines is marketed as a targeted topical alternative for specific expression lines and is sold exclusively through licensed dermatologist and medical aesthetic practices. L'Oréal acquired the brand in 2024.

Brand founded: 2016 · Product launched: 2018

Myth vs. Reality

Myth

Argireline-based creams work as well as Botox.

Reality

They don't. Topical muscle-signaling peptides produce subtle, modest effects that are measurable in some clinical studies but nowhere near the magnitude of injected neurotoxins. If dramatic line reduction is the goal, injectables are the tool; this is a supplement, not a substitute.

Myth

You only need to apply this once a day since the peptides last.

Reality

Twice-daily application is recommended for consistent signaling to the muscle and fibroblast pathways. The peptides have a short half-life on the skin and need to be replenished regularly.

FAQ

Common Praise

"subtle smoothing effect on expression lines"

"gentle enough for sensitive skin"

"no pilling under makeup"

"small applicator makes it last"

Common Complaints

"expensive for the small size"

"subtle rather than dramatic results"

"not a replacement for injectables"

"overstated marketing claims"

Notable Endorsements

Dermatologist offices nationwide

Appears In

best topical expression line treatment best argireline cream best peptide spot treatment best alternative to botox for sensitive skin

Related Conditions

aging

Related Ingredients

peptides niacinamide hyaluronic acid